ATE318591T1 - Pharmazeutische zusammensetzung zur behandlung von fettleibigkeit - Google Patents

Pharmazeutische zusammensetzung zur behandlung von fettleibigkeit

Info

Publication number
ATE318591T1
ATE318591T1 AT01274819T AT01274819T ATE318591T1 AT E318591 T1 ATE318591 T1 AT E318591T1 AT 01274819 T AT01274819 T AT 01274819T AT 01274819 T AT01274819 T AT 01274819T AT E318591 T1 ATE318591 T1 AT E318591T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
treating obesity
obesity
sarcosine
sbs
Prior art date
Application number
AT01274819T
Other languages
English (en)
Inventor
Avner Shenfeld
Meir Shinitzky
Original Assignee
Lean Ex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lean Ex Ltd filed Critical Lean Ex Ltd
Application granted granted Critical
Publication of ATE318591T1 publication Critical patent/ATE318591T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01274819T 2001-11-26 2001-11-26 Pharmazeutische zusammensetzung zur behandlung von fettleibigkeit ATE318591T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2001/002227 WO2003045370A1 (en) 2001-11-26 2001-11-26 Pharmaceutical composition for treating obesity

Publications (1)

Publication Number Publication Date
ATE318591T1 true ATE318591T1 (de) 2006-03-15

Family

ID=11004216

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01274819T ATE318591T1 (de) 2001-11-26 2001-11-26 Pharmazeutische zusammensetzung zur behandlung von fettleibigkeit

Country Status (6)

Country Link
EP (1) EP1455774B1 (de)
AT (1) ATE318591T1 (de)
AU (1) AU2002220943A1 (de)
DE (1) DE60117472T2 (de)
ES (1) ES2259650T3 (de)
WO (1) WO2003045370A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031214A1 (ja) * 2002-10-07 2004-04-15 National Institute Of Advanced Industrial Science And Technology 分子配向の揃った球状微粒子、それを用いた球状マイクロカプセル及びそれらの製造方法
WO2007013062A1 (en) * 2005-07-25 2007-02-01 Lean-Ex Ltd. Composition and method for weight maintenance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU83422A1 (fr) * 1981-06-09 1983-04-06 Galephar Sels de nitrofurantoine,leur preparation et leur utilisation
CA1213888A (en) * 1983-09-28 1986-11-12 Warner-Lambert Company L-arginine isoxicamate
IL101708A (en) * 1992-04-28 1996-08-04 Senyorina Ltd Anti-fattening drugs comprising amino acid derivatives

Also Published As

Publication number Publication date
WO2003045370A1 (en) 2003-06-05
AU2002220943A1 (en) 2003-06-10
EP1455774B1 (de) 2006-03-01
ES2259650T3 (es) 2006-10-16
DE60117472D1 (de) 2006-04-27
EP1455774A1 (de) 2004-09-15
DE60117472T2 (de) 2006-09-28

Similar Documents

Publication Publication Date Title
RU94041950A (ru) Использование соединений ряда 3-аролоксипропиламинов в лечении недержания
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
DE60117043D1 (de) Behandlung von mukositis
BR0309546A (pt) Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii
ATE204754T1 (de) Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
BR0310092A (pt) Combinação de compostos orgânicos
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
DE60140426D1 (de) Pharmazeutische zusammensetzung für muskelanabolismus
BRPI0417101A (pt) uso de compostos de peptìdeo para tratamento de dor neuropática central
BRPI0410316A (pt) composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
DE60233433D1 (de) PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE60231969D1 (de) sPLA2-INHIBITOREN ZUR BEHANDLUNG VON ARTERIOSKLEROSE
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
NO20041378L (no) [[2-(Amino-3,4-diokso-1-cyklobuten-1-yl)amino]alkyl]-syrederivater for behandling av smerte
ATE318591T1 (de) Pharmazeutische zusammensetzung zur behandlung von fettleibigkeit
BR9909870A (pt) Pirrolidinas como inibidores de neuraminidases
ATE289196T1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DE60216457D1 (de) Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten
DE602004019778D1 (de) Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen
BRPI0411245A (pt) composto, composição farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de vìrus oncogênicos e para tratamento ou profilaxia de condições ou distúrbios devidos a infecção por hpv

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1455774

Country of ref document: EP

REN Ceased due to non-payment of the annual fee